Ann: ePAT selected for CSIRO's ON Accelerator Program-MNQ.AX, page-37

Longtime ResApp Investor here (originally bought into RAP at a very similar price as MNQ is today).I have bought in today - downside looks limited from here. This looks very interesting to say the least. There are many similarities between this and RAP in terms of funding and regulatory pathways. Main points from my research:

- Technology Developed in Curtin University
- Licensed the 3D facial recognition software from a Swiss Company
- 2 Versions are being developed. One for elderly dementia patients and another for children who are unable to speak.
- World first pain assessment tool which uses facial recognition technology
- Currently 47.5M Dementia patients globally with 80% said to experience pain regularly (re-occuring revenue?)
- App already has excellent correlation with the current subjective Abbey pain scale.
- Further implementation studies this year with approval mid 2017.
- CSIRO fast tracked

FDA approval would be very interesting, surely a similar path as RAP. In my opinion this app could have an even easier path as its not a strict life or death scenario and again would be used under the surveillance of a caretaker, nurse etc. I would also like to invite a few RAPpers to share their view. @Lefevre @Red bar @Wise_One @ClownTrader